Mereo BioPharma Group (MREO) Stock Forecast: StockMap's 2-Week Call
MREO stock forecast: StockMap's model makes no two-week call on Mereo BioPharma Group after the Nov 19 close: its evidence is split, 4 reasons for and 11 against. Right in 3 of 6 two-week windows on MREO since Aug 21; by chance, a call on the same dates was right 58% of the time.
Mereo BioPharma Group last closed at $0.28, -3.45% on the session.
Against the IVW growth benchmark the position is -1.12% over the forecast window.
Mereo BioPharma Group's market cap is $44.61M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -8 (too close to call).
Where MREO sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
39 daily calls for MREO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Mereo BioPharma Group in the 14th percentile on return on equity, where 100 is best.
Mereo BioPharma Group is classified under Health Care / Biotechnology.
StockMap tracks Mereo BioPharma Group as the 314th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Mereo BioPharma Group ranks 101st of 394 in the group, against a group median of -0.27.